DNA Script SAS
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
DNA Script SAS - overview
Established
2014
Location
-, -, France
Primary Industry
Biotechnology
About
Based in Le Kremlin-Bicêtre, France, and founded in 2014 by Sylvain Gariel, Thomas Ybert, and Xavier Godron, DNA Script Inc. develops and provides template-free enzymatic technology for synthetic DNA (Deoxyribonucleic acid) production. In October 2021, DNA Script SAS raised USD 165 million in a Series C funding co-led by Catalio Capital Management, Coatue Management with participation from ArrowMark Partners, Columbia Threadneedle Investments, Farallon Capital Management, Fidelity Investments, Moore Strategic Ventures, Alexandria Venture Investments, Agilent Technologies, Bpifrance Investissement, Casdin Capital, Danaher Corporation, Illumina Ventures, Kurma Partners, Life Sciences Partners, and M Ventures. DNA Script SAS has raised a total of USD 297.
87 million in funding and co-founder Thomas Ybert is its CEO. DNA Script SAS’s product line includes the Syntax system, Syntax 60-cycle kit, 96 oligos, and Syntax software suite. The Syntax system is powered by Enzymatic DNA Synthesis (EDS) technology is a DNA printer that enables the on-demand synthesis of custom DNA oligos in a benchtop solution. Syntax 60-cycle kit, 96 oligos is also powered with EDS technology for template-free synthesis.
The Syntax software suite is an intuitive, remote interface for seamless planning and automation. DNA Script has developed an alternative to traditional DNA synthesis, which is Enzymatic DNA Synthesis (EDS) that allows technology to be feasible for the labs with the Syntax System. The company has generated a revenue of USD 1. 009 million in the financial year 2019 and for 2018, the revenue was USD 0.
01 million. DNA Script plans to use its proceeds from a Series C funding to accelerate the expansion and commercialization of its SYNTAX Platform and broaden its portfolio of products powered by EDS.
Current Investors
Sofinnova Partners, Idinvest Partners, M Ventures
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Molecular Science, Genetics & Gene Therapy, Diagnostic Equipment, Pharmaceutical Research & Development
Website
www.dnascript.com
Company Stage
Series C
Total Amount Raised
Subscriber access only
DNA Script SAS - financials
| Fiscal Year Ended | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue (USD) | 9,800 | 1,009,316 | 1,693,127 | 4,796,589.4 | - | - | - |
| % Revenue Growth (YoY) | - | 10199.1% | 67.7% | 183.3% | - | - | - |
| EBITDA (USD) | 4,518,273 | 6,232,036 | (11,884,702) | (26,914,287.3) | - | - | - |
| Operating Income (USD) | 4,344,136 | 5,823,670 | (14,228,491) | (31,218,367.7) | - | - | - |
| Operating Margin | 44327.9% | 577.0% | (840.4%) | (650.8%) | - | - | - |
| % EBITDA Margin | 46104.8% | 617.5% | (701.9%) | (561.1%) | - | - | - |
| NET Income (USD) | 3,770,676 | 5,164,676 | (12,856,921) | (28,683,569.2) | - | - | - |
| % Net Margin | 38476.3% | 511.7% | (759.4%) | (598.0%) | - | - | - |
DNA Script SAS - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Board Member | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.